Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 25, 1999

View Archived Issues

Amrad: Annual Report 1998

Corixa is first to achieve clinical testing of a microsphere-encapsulated peptide cancer vaccine

Experiments show skeletal muscle capable of bone formation when transplanted into animals

CytRx reaches midpoint in Flocor trial

Orphan Medical begins Treatment IND trial of Xyrem in narcolepsy

Axcan and Labopharm to develop controlled-release trimebutine formulation

Connetics begins pivotal trial of relaxin for scleroderma therapy

New compounds from Pharmacia & Upjohn interfere in the kynurenine metabolic pathway

New Lilly SERMs especially useful for breast cancer

Ilex Oncology initiates phase III trial of DFMO

ICE/ced-3 cysteine protease inhibitors in development at Idun

FDA grants priority review status to U.S. Bioscience's sNDA for Ethyol

Tachykinin antagonists specifically claimed for asthma by Merck

NNRTIs from Boehringer Ingelheim effective against mutant viruses

Status updated for Esteve's atypical antipsychotic E-5842

Taiwan university researchers present new ATP-sensitive potassium channel opener

AutoImmune and Teva to collaborate on oral immune therapies

Advisory committee votes not to recommend approval of Relenza

Aurora enters assay development and screening agreement with P&U

Strategic review of Novopharm Biotech's R&D program leads to discontinuation of GPI-2A

New tradename announced for Magainin's pexiganan

Celtrix adds another patent to its SomatoKine portfolio

AC-178335: new pure somatostatin antagonist that induces GH release in vivo

Orally active TxA2 antagonist in clinical development at Zeria

MS&D launches alopecia treatment in Spain

Healing of severe esophagitis linked to improvement in peristaltic dysfunction

Preclinical study confirms antiinflammatory activity of raxofelast

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...